NTRK1重排组织细胞增生症的临床病理与分子特征
国际协作研究50例pan-TRK表达和/或NTRK框内重排的组织细胞增生症,并分析45例对照黄色肉芽肿。所有病例呈黄色肉芽肿组织学,50例pan-TRK均阳性而45例无NTRK融合的对照均阴性;NTRK1融合伴侣以IRF2BP2(23/46)和TPM3(12/46)最常见。临床结局良好,包括3/4例全身性疾病新生儿自发消退及2例脑或支气管病变患者对拉罗替尼快速应答。
要点
- 50例中88%病变局限于皮肤,41例为单个皮肤结节、3例为多发皮肤病变。
- 4例新生儿表现为皮肤病变、肝大和需输注的血小板减少。
- 50例pan-TRK均阳性,45例无NTRK框内融合的对照黄色肉芽肿均阴性。
核心结论
- 本研究推进了组织细胞增生症的分子特征描述,可能指导患者诊断和个体化治疗。
研究设计与样本
- 通过国际合作研究50例pan-TRK表达和/或NTRK框内重排的组织细胞增生症病例,并分析45例对照黄色肉芽肿。
- 对切片进行集中审阅,收集临床和分子数据,对照采用pan-TRK免疫组化和靶向RNA测序。
主要发现
- 50例包括30名儿童和20名成人,中位年龄11.5岁(范围0-73岁),男性占64%。
- 88%患者病变局限于皮肤,其中41例为单个皮肤结节、3例为多发皮肤病变。
- 4例新生儿表现为皮肤病变、肝大和需输注的血小板减少,其余2例有脑或支气管危及生命的病变。
- 所有病例呈黄色肉芽肿组织学,常包括泡沫样组织细胞和Touton巨细胞。
- 50/50例组织细胞pan-TRK染色阳性,45/45例无NTRK框内融合的对照黄色肉芽肿染色阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-Langerhans cell histiocytoses are a diverse group of histiocytic diseases. Different entities are defined based on clinical, histopathologic, and/or molecular characteristics. This study aimed to define NTRK-rearranged histiocytosis. Through international collaboration, we investigated 50 cases of histiocytosis with pan-tropomyosin receptor kinase (pan-TRK) expression and/or in-frame NTRK rearrangement. We also analyzed 45 control xanthogranulomas using pan-TRK immunohistochemistry and targeted RNA sequencing. Slides were centrally reviewed; clinical and molecular data were collected. The 50 cases comprised 30 children and 20 adults with a median age of 11.5 years (range, 0-73 years) and a male predominance (64%). Most patients (88%) had disease limited to the skin, including a single skin nodule in 41 patients and multiple skin lesions in 3 others. Four newborns presented with skin lesions, hepatomegaly, and thrombocytopenia that required transfusions. The 2 remaining patients had life-threatening lesions of the brain or bronchus. All cases displayed xanthogranuloma histology, often including foamy histiocytes and Touton giant cells. Histiocytes stained positive for pan-TRK in 50 of 50 cases, whereas all 45 control xanthogranulomas without in-frame NTRK fusions stained negative. NTRK1 fusion partners included IRF2BP2 (23/46), TPM3 (12/46), SQSTM1 (3/46), PRDX1 (3/46), NPM1 (2/46), LMNA (2/46), and ARHGEF2 (1/46). Clinical outcomes were favorable, including spontaneous disease regression in 3 of 4 newborns with systemic disease, and rapid clinical response in both patients with a brain or bronchial tumor treated with the TRK inhibitor larotrectinib. This study advances the molecular characterization of histiocytoses and may guide the diagnosis and personalized treatment of patients.
引用
- Fragneau R, Fraitag S, Kemps PG, et al. NTRK1-rearranged histiocytosis: clinicopathologic and molecular features. Blood Adv. 2025. PMID: 40315374. doi:10.1182/bloodadvances.2025016167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。